236 related articles for article (PubMed ID: 1310767)
21. Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds.
Madani N; Princiotto AM; Zhao C; Jahanbakhshsefidi F; Mertens M; Herschhorn A; Melillo B; Smith AB; Sodroski J
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881646
[TBL] [Abstract][Full Text] [Related]
22. Human immunodeficiency virus type 1 uses lipid raft-colocalized CD4 and chemokine receptors for productive entry into CD4(+) T cells.
Popik W; Alce TM; Au WC
J Virol; 2002 May; 76(10):4709-22. PubMed ID: 11967288
[TBL] [Abstract][Full Text] [Related]
23. Transduction of bone-marrow-derived mesenchymal stem cells by using lentivirus vectors pseudotyped with modified RD114 envelope glycoproteins.
Zhang XY; La Russa VF; Reiser J
J Virol; 2004 Feb; 78(3):1219-29. PubMed ID: 14722277
[TBL] [Abstract][Full Text] [Related]
24. Pseudotypes of vesicular stomatitis virus-bearing envelope antigens of certain HIV-1 strains permissively infect human syncytiotrophoblasts cultured in vitro: implications for in vivo infection of syncytiotrophoblasts by cell-free HIV-1.
Bácsi A; Ebbesen P; Szabó J; Beck Z; Andirkó I; Csoma E; Tóth FD
J Med Virol; 2001 Aug; 64(4):387-97. PubMed ID: 11468721
[TBL] [Abstract][Full Text] [Related]
25. Monitoring Viral Entry in Real-Time Using a Luciferase Recombinant Vesicular Stomatitis Virus Producing SARS-CoV-2, EBOV, LASV, CHIKV, and VSV Glycoproteins.
Lay Mendoza MF; Acciani MD; Levit CN; Santa Maria C; Brindley MA
Viruses; 2020 Dec; 12(12):. PubMed ID: 33348746
[TBL] [Abstract][Full Text] [Related]
26. Vaccinia virus recombinants: expression of VSV genes and protective immunization of mice and cattle.
Mackett M; Yilma T; Rose JK; Moss B
Science; 1985 Jan; 227(4685):433-5. PubMed ID: 2981435
[TBL] [Abstract][Full Text] [Related]
27. Immunogenicity of an aphthovirus chimera of the glycoprotein of vesicular stomatitis virus.
Grigera PR; Garcia-Briones M; Periolo O; la Torre JL; Wagner RR
J Virol; 1996 Dec; 70(12):8492-501. PubMed ID: 8970972
[TBL] [Abstract][Full Text] [Related]
28. Resistance of primary isolates of human immunodeficiency virus type 1 to neutralization by soluble CD4 is not due to lower affinity with the viral envelope glycoprotein gp120.
Turner S; Tizard R; DeMarinis J; Pepinsky RB; Zullo J; Schooley R; Fisher R
Proc Natl Acad Sci U S A; 1992 Feb; 89(4):1335-9. PubMed ID: 1741386
[TBL] [Abstract][Full Text] [Related]
29. Human immunodeficiency virus type 2 envelope glycoprotein: differential CD4 interactions of soluble gp120 versus the assembled envelope complex.
Mulligan MJ; Ritter GD; Chaikin MA; Yamshchikov GV; Kumar P; Hahn BH; Sweet RW; Compans RW
Virology; 1992 Mar; 187(1):233-41. PubMed ID: 1736526
[TBL] [Abstract][Full Text] [Related]
30. The cytoplasmic and transmembrane domains of the vaccinia virus B5R protein target a chimeric human immunodeficiency virus type 1 glycoprotein to the outer envelope of nascent vaccinia virions.
Katz E; Wolffe EJ; Moss B
J Virol; 1997 Apr; 71(4):3178-87. PubMed ID: 9060681
[TBL] [Abstract][Full Text] [Related]
31. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.
Wyatt R; Moore J; Accola M; Desjardin E; Robinson J; Sodroski J
J Virol; 1995 Sep; 69(9):5723-33. PubMed ID: 7543586
[TBL] [Abstract][Full Text] [Related]
32. R5 HIV env and vesicular stomatitis virus G protein cooperate to mediate fusion to naive CD4+ T Cells.
Pace MJ; Agosto L; O'Doherty U
J Virol; 2011 Jan; 85(1):644-8. PubMed ID: 20980513
[TBL] [Abstract][Full Text] [Related]
33. A genetically engineered spleen necrosis virus-derived retroviral vector that displays the HIV type 1 glycoprotein 120 envelope peptide.
Jiang A; Fisher H; Pomerantz RJ; Dornburg R
Hum Gene Ther; 1999 Nov; 10(16):2627-36. PubMed ID: 10566890
[TBL] [Abstract][Full Text] [Related]
34. Induction of Tier 1 HIV Neutralizing Antibodies by Envelope Trimers Incorporated into a Replication Competent Vesicular Stomatitis Virus Vector.
Bresk CA; Hofer T; Wilmschen S; Krismer M; Beierfuß A; Effantin G; Weissenhorn W; Hogan MJ; Jordan APO; Gelman RS; Montefiori DC; Liao HX; Schmitz JE; Haynes BF; von Laer D; Kimpel J
Viruses; 2019 Feb; 11(2):. PubMed ID: 30769947
[TBL] [Abstract][Full Text] [Related]
35. Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor.
Hill CM; Deng H; Unutmaz D; Kewalramani VN; Bastiani L; Gorny MK; Zolla-Pazner S; Littman DR
J Virol; 1997 Sep; 71(9):6296-304. PubMed ID: 9261346
[TBL] [Abstract][Full Text] [Related]
36. Lack of correlation between soluble CD4-induced shedding of the human immunodeficiency virus type 1 exterior envelope glycoprotein and subsequent membrane fusion events.
Thali M; Furman C; Helseth E; Repke H; Sodroski J
J Virol; 1992 Sep; 66(9):5516-24. PubMed ID: 1501286
[TBL] [Abstract][Full Text] [Related]
37. Production of high-titer human immunodeficiency virus type 1 pseudotyped with vesicular stomatitis virus glycoprotein.
Bartz SR; Vodicka MA
Methods; 1997 Aug; 12(4):337-42. PubMed ID: 9245614
[TBL] [Abstract][Full Text] [Related]
38. Expression of additional genes in a vector derived from a minimal RNA virus.
Rolls MM; Haglund K; Rose JK
Virology; 1996 Apr; 218(2):406-11. PubMed ID: 8610469
[TBL] [Abstract][Full Text] [Related]
39. Prediction and identification of a permissive epitope insertion site in the vesicular stomatitis virus glycoprotein.
Schlehuber LD; Rose JK
J Virol; 2004 May; 78(10):5079-87. PubMed ID: 15113889
[TBL] [Abstract][Full Text] [Related]
40. Human immunodeficiency virus type 1 particles pseudotyped with envelope proteins that fuse at low pH no longer require Nef for optimal infectivity.
Chazal N; Singer G; Aiken C; Hammarskjöld ML; Rekosh D
J Virol; 2001 Apr; 75(8):4014-8. PubMed ID: 11264394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
